NL300238I2 - Gehumaniseerde antilichamen tegen leukocytenadhesiemolecule VLA-4- - Google Patents
Gehumaniseerde antilichamen tegen leukocytenadhesiemolecule VLA-4-Info
- Publication number
- NL300238I2 NL300238I2 NL300238C NL300238C NL300238I2 NL 300238 I2 NL300238 I2 NL 300238I2 NL 300238 C NL300238 C NL 300238C NL 300238 C NL300238 C NL 300238C NL 300238 I2 NL300238 I2 NL 300238I2
- Authority
- NL
- Netherlands
- Prior art keywords
- antibodies against
- humanized antibodies
- adhesion molecule
- leukocyte adhesion
- against leukocyte
- Prior art date
Links
- 108010008212 Integrin alpha4beta1 Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18626994A | 1994-01-25 | 1994-01-25 | |
| PCT/US1995/001219 WO1995019790A1 (en) | 1994-01-25 | 1995-01-25 | Humanized antibodies against leukocyte adhesion molecule vla-4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300238I1 NL300238I1 (en:Method) | 2006-10-02 |
| NL300238I2 true NL300238I2 (nl) | 2007-05-01 |
Family
ID=22684288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300238C NL300238I2 (nl) | 1994-01-25 | 2006-08-02 | Gehumaniseerde antilichamen tegen leukocytenadhesiemolecule VLA-4- |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1759709B1 (en:Method) |
| JP (5) | JP4115517B2 (en:Method) |
| KR (1) | KR100367948B1 (en:Method) |
| CN (1) | CN1211123C (en:Method) |
| AT (1) | ATE333895T1 (en:Method) |
| AU (1) | AU703152B2 (en:Method) |
| CA (1) | CA2182013C (en:Method) |
| DE (2) | DE122006000043I1 (en:Method) |
| DK (2) | DK1759709T3 (en:Method) |
| ES (2) | ES2270425T3 (en:Method) |
| FI (1) | FI117509B (en:Method) |
| FR (1) | FR06C0024I2 (en:Method) |
| HU (1) | HU220799B1 (en:Method) |
| LU (1) | LU91271I2 (en:Method) |
| MX (1) | MX9602971A (en:Method) |
| NL (1) | NL300238I2 (en:Method) |
| NO (3) | NO319867B1 (en:Method) |
| NZ (1) | NZ279730A (en:Method) |
| PL (1) | PL181827B1 (en:Method) |
| PT (1) | PT804237E (en:Method) |
| WO (1) | WO1995019790A1 (en:Method) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307025B1 (en) | 1989-04-28 | 2001-10-23 | Biogen, Inc. | VCAM fusion proteins and DNA coding therefor |
| US5871734A (en) * | 1992-01-13 | 1999-02-16 | Biogen, Inc. | Treatment for asthma with VLA-4 blocking agents |
| US5932214A (en) | 1994-08-11 | 1999-08-03 | Biogen, Inc. | Treatment for inflammatory bowel disease with VLA-4 blockers |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| ATE161730T1 (de) * | 1993-02-09 | 1998-01-15 | Biogen Inc | Antikörper zur behandlung von insulinabhängigen diabetes |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7750137B2 (en) | 1995-09-01 | 2010-07-06 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressins |
| US6551593B1 (en) | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| AU7348798A (en) * | 1997-05-09 | 1998-12-08 | John P. Robarts Research Institute, The | Method for dislodging infiltrated leukocytes from a tissue |
| DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
| DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| US7618630B2 (en) | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| HU229038B1 (hu) * | 1998-09-14 | 2013-07-29 | Regents Board Of | A mielóma multiplex és a mielóma indukált csontreszorpció kezelése integrin antagonistákkal |
| ATE298249T1 (de) * | 1999-04-22 | 2005-07-15 | Biogen Idec Inc | Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit |
| DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| NZ515686A (en) | 1999-06-01 | 2005-01-28 | Biogen Inc | A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| ES2415708T3 (es) * | 1999-12-16 | 2013-07-26 | Biogen Idec Ma Inc. | Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4 |
| DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| ATE471344T1 (de) | 2001-04-13 | 2010-07-15 | Biogen Idec Inc | Antikörper gegen vla-1 |
| DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
| AU2003213231A1 (en) | 2002-02-25 | 2003-09-09 | Elan Pharmaceuticals, Inc. | Administration of agents for the treatment of inflammation |
| US7371383B2 (en) * | 2002-04-12 | 2008-05-13 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
| GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| AR040778A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| CA2510180C (en) * | 2002-12-17 | 2012-09-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| EP2803667A1 (en) | 2003-12-22 | 2014-11-19 | Ajinomoto Co., Inc. | Phenylalanine derivatives |
| EP1827491A4 (en) * | 2004-11-19 | 2010-07-14 | Biogen Idec Inc | TREATMENT OF MULTIPLE SCLEROSIS |
| WO2007061679A1 (en) * | 2005-11-17 | 2007-05-31 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN |
| AU2007267579B2 (en) | 2006-05-25 | 2013-05-30 | Biogen Ma Inc. | Methods of treating stroke |
| EP2124996A4 (en) | 2007-02-20 | 2010-03-24 | Merrimack Pharmaceuticals Inc | METHOD FOR TREATING MULTIPLE SCLEROSIS BY ADMINISTERING AN ALPHA FETOPROTEIN COMBINED WITH AN INTEGRINANT AGONIST |
| PT2170390T (pt) * | 2007-06-14 | 2019-02-12 | Biogen Ma Inc | Formulações com anticorpo natalizumab |
| ES2466020T3 (es) | 2007-12-13 | 2014-06-09 | Tokuyama Corporation | Composición fotocrómica curable |
| WO2009126920A2 (en) | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| TWI466681B (zh) | 2009-03-20 | 2015-01-01 | Amgen Inc | α４β７雜二聚體專一性拮抗抗體 |
| US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
| RS60897B1 (sr) | 2010-04-16 | 2020-11-30 | Biogen Ma Inc | Anti-vla-4 antitela |
| CA2834900C (en) | 2011-05-02 | 2021-03-02 | Millennium Pharmaceuticals, Inc. | Formulation for anti-.alpha.4.beta.7 antibody |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| US10160808B2 (en) | 2012-02-16 | 2018-12-25 | Santarus, Inc. | Anti-VLA1 (CD49A) antibody pharmaceutical compositions |
| US20190225694A1 (en) | 2016-06-28 | 2019-07-25 | Zaklady Farmaceutyczne Polpharma Sa | Recombinant production of monoclonal antibodies |
| EP3541413A2 (en) | 2016-11-21 | 2019-09-25 | Polpharma Biologics S.A. | Aqueous pharmaceutical formulations |
| EP3583126B1 (en) * | 2017-02-17 | 2025-08-27 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| EP3635093A1 (en) | 2017-06-08 | 2020-04-15 | Polpharma Biologics S.A. | Improved methods of cell culture |
| CN119080931A (zh) | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| US20240301512A1 (en) | 2021-01-29 | 2024-09-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| IL95501A (en) * | 1989-09-01 | 1997-04-15 | Hutchinson Fred Cancer Res | Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies |
| WO1993015764A1 (en) * | 1992-02-12 | 1993-08-19 | Biogen, Inc. | Treatment for inflammatory bowel disease |
| DK0678122T3 (da) * | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| AUPP647298A0 (en) | 1998-10-13 | 1998-11-05 | Keystone Retaining Wall Systems, Inc. | Retaining wall block |
-
1995
- 1995-01-25 PL PL95315634A patent/PL181827B1/pl unknown
- 1995-01-25 AT AT95908741T patent/ATE333895T1/de active
- 1995-01-25 DE DE1995635133 patent/DE122006000043I1/de active Pending
- 1995-01-25 ES ES95908741T patent/ES2270425T3/es not_active Expired - Lifetime
- 1995-01-25 DK DK06013916.9T patent/DK1759709T3/da active
- 1995-01-25 HU HU9602019A patent/HU220799B1/hu active Protection Beyond IP Right Term
- 1995-01-25 NZ NZ279730A patent/NZ279730A/en not_active IP Right Cessation
- 1995-01-25 DK DK95908741T patent/DK0804237T3/da active
- 1995-01-25 ES ES06013916T patent/ES2424292T3/es not_active Expired - Lifetime
- 1995-01-25 AU AU16960/95A patent/AU703152B2/en not_active Expired
- 1995-01-25 WO PCT/US1995/001219 patent/WO1995019790A1/en active IP Right Grant
- 1995-01-25 JP JP51977095A patent/JP4115517B2/ja not_active Expired - Lifetime
- 1995-01-25 CA CA002182013A patent/CA2182013C/en not_active Expired - Lifetime
- 1995-01-25 KR KR1019960703987A patent/KR100367948B1/ko not_active Expired - Lifetime
- 1995-01-25 CN CNB951913549A patent/CN1211123C/zh not_active Expired - Lifetime
- 1995-01-25 PT PT95908741T patent/PT804237E/pt unknown
- 1995-01-25 DE DE69535133T patent/DE69535133T2/de not_active Expired - Lifetime
- 1995-01-25 EP EP06013916A patent/EP1759709B1/en not_active Expired - Lifetime
- 1995-01-25 EP EP95908741A patent/EP0804237B8/en not_active Expired - Lifetime
-
1996
- 1996-07-24 NO NO19963097A patent/NO319867B1/no not_active IP Right Cessation
- 1996-07-24 FI FI962958A patent/FI117509B/fi active Protection Beyond IP Right Term
- 1996-07-24 MX MX9602971A patent/MX9602971A/es unknown
-
2005
- 2005-08-05 JP JP2005228930A patent/JP2006045237A/ja not_active Withdrawn
-
2006
- 2006-07-27 FR FR06C0024C patent/FR06C0024I2/fr active Active
- 2006-08-02 LU LU91271C patent/LU91271I2/fr unknown
- 2006-08-02 NL NL300238C patent/NL300238I2/nl unknown
- 2006-08-07 NO NO2006008C patent/NO2006008I2/no unknown
-
2009
- 2009-05-18 JP JP2009120421A patent/JP2009235078A/ja not_active Withdrawn
-
2013
- 2013-02-18 JP JP2013028635A patent/JP5487382B2/ja not_active Expired - Lifetime
- 2013-03-18 JP JP2013054628A patent/JP2013165718A/ja not_active Withdrawn
-
2017
- 2017-08-01 NO NO2017040C patent/NO2017040I2/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300238I2 (nl) | Gehumaniseerde antilichamen tegen leukocytenadhesiemolecule VLA-4- | |
| DK0724456T3 (da) | CD40-Antistoffer | |
| DE69636748D1 (de) | Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien | |
| ES2173130T3 (es) | Metodo de fijacion de material al peptido beta-amiloide. | |
| ES2106195T3 (es) | Anticuerpo igg aglicosilado anti cd3. | |
| MY154009A (en) | Anti-alpha v beta 6 antibodies | |
| ATE218387T1 (de) | Antikörperreinigung | |
| ATE531812T1 (de) | Humanisierung von nager-antikörpern | |
| DE59209129D1 (de) | Verwendung von Antikörper enthaltenden Präparationen zur Immunsuppression | |
| NO20010747D0 (no) | Antitrombotisk middel og humanisert anti-von Willebrand faktor monoklonalt antistoff | |
| DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
| ATE206621T1 (de) | Il-8 antagonisten zur behandlung von asthma | |
| ATE222927T1 (de) | Monoklonaler antikörper gegen den tumorzytotoxischen faktor ii (tcf-ii) |